TLR9 and metabolic dysfunction-associated steatohepatitis: And strikingly, treatment with a TLR9 antagonist treatment has been found to be effective in treating NASH, suggesting that targeting TLR9 signaling may be a promising therapeutic strategy for this disease (63).